JOP20180121A1 - أجسام مضادة ضد عامل التخثر xi - Google Patents

أجسام مضادة ضد عامل التخثر xi

Info

Publication number
JOP20180121A1
JOP20180121A1 JOP/2018/0121A JOP20180121A JOP20180121A1 JO P20180121 A1 JOP20180121 A1 JO P20180121A1 JO P20180121 A JOP20180121 A JO P20180121A JO P20180121 A1 JOP20180121 A1 JO P20180121A1
Authority
JO
Jordan
Prior art keywords
coagulation factor
antibodies
activation
fxia
apl
Prior art date
Application number
JOP/2018/0121A
Other languages
Arabic (ar)
English (en)
Inventor
Oldham Elizabeth
Ganti Vaishnavi
Tabrizifard Mohammad
P Ellsworth Kenneth
Seiffert Dietmar
Prinz Bianka
Chen Zhu
Milligan James
Original Assignee
Adimab Llc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc, Merck Sharp & Dohme filed Critical Adimab Llc
Publication of JOP20180121A1 publication Critical patent/JOP20180121A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
JOP/2018/0121A 2016-06-14 2017-06-16 أجسام مضادة ضد عامل التخثر xi JOP20180121A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14
PCT/US2017/036940 WO2017218371A1 (en) 2016-06-14 2017-06-12 Anti-coagulation factor xi antibodies

Publications (1)

Publication Number Publication Date
JOP20180121A1 true JOP20180121A1 (ar) 2018-12-12

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0121A JOP20180121A1 (ar) 2016-06-14 2017-06-16 أجسام مضادة ضد عامل التخثر xi

Country Status (29)

Country Link
US (6) US10676536B2 (https=)
EP (1) EP3469002A1 (https=)
JP (2) JP7022081B2 (https=)
KR (2) KR102379580B1 (https=)
CN (2) CN116425879A (https=)
AR (1) AR108717A1 (https=)
AU (3) AU2017286432B2 (https=)
BR (1) BR112018075858A2 (https=)
CA (2) CA3172367A1 (https=)
CL (2) CL2018003565A1 (https=)
CO (1) CO2018013434A2 (https=)
CR (1) CR20180583A (https=)
DO (1) DOP2018000284A (https=)
EA (1) EA201892716A1 (https=)
EC (1) ECSP18091593A (https=)
GE (2) GEAP202114983A (https=)
IL (2) IL315266A (https=)
JO (1) JOP20180121A1 (https=)
MA (1) MA45234A (https=)
MX (2) MX2018015757A (https=)
MY (1) MY201852A (https=)
NI (1) NI201800134A (https=)
PE (1) PE20190416A1 (https=)
PH (1) PH12018502586A1 (https=)
SG (2) SG10202103120UA (https=)
TN (1) TN2018000417A1 (https=)
TW (2) TWI752964B (https=)
UA (1) UA129793C2 (https=)
WO (1) WO2017218371A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL315266A (en) * 2016-06-14 2024-10-01 Merck Sharp ַ& Dohme Llc Anti-coagulation factor xi antibodies
AU2017383232B2 (en) 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CA3188566A1 (en) * 2020-07-03 2022-01-06 Suzhou Alphamab Co., Ltd. Coagulation factor xi (fxi) binding protein
CA3207703A1 (en) 2021-02-09 2022-08-18 Jonas Hallen Anti-s100a4 humanized antibodies, uses and methods
EP4442273A4 (en) * 2021-11-30 2025-12-24 Suzhou Alphamab Co Ltd METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOEMBOLIC DISEASES
CN120858120A (zh) * 2022-12-30 2025-10-28 甘李药业股份有限公司 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
AR045056A1 (es) 2003-07-15 2005-10-12 Amgen Inc Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
MY157915A (en) 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EA017812B1 (ru) 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
MX2008014978A (es) 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
EP2064244B1 (en) 2006-08-03 2019-06-05 MedImmune Limited ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
EP2497783A3 (en) 2007-09-26 2013-04-17 U3 Pharma GmbH Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
JP2011504371A (ja) * 2007-11-21 2011-02-10 オレゴン ヘルス アンド サイエンス ユニバーシティー 抗第ｘｉ因子モノクローナル抗体およびその使用方法
AU2016203944A1 (en) 2007-11-21 2016-07-07 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TR201820051T4 (tr) 2008-06-19 2019-01-21 Prothix Bv Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
RS55861B1 (sr) 2008-10-31 2017-08-31 Janssen Biotech Inc Antagonisti toll-like receptora 3
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
PT2373691T (pt) * 2008-12-18 2019-05-08 Univ Vanderbilt Anticorpos anti-fxi e métodos de utilização
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
PE20120835A1 (es) 2009-04-16 2012-07-23 Abbvie Biotherapeutics Inc Anticuerpos anti-tnf-alfa y sus usos
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
WO2011045704A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US9045536B2 (en) 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
WO2011097329A2 (en) * 2010-02-03 2011-08-11 Trilogy Ip Holdings, Inc. Mobile communication plan offerings
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
SG191716A1 (en) 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
HUE031089T2 (en) 2012-04-13 2017-06-28 Rottapharm Biotech Srl Anti-ADAMTS-5 antibody, derivatives and uses
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
CA2872018A1 (en) 2012-05-17 2013-11-21 Sorrento Therapeutics, Inc. Antigen binding proteins that bind egfr
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CA2925057A1 (en) 2013-10-01 2015-04-09 Simon T. BARRY Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
BR112016021576A2 (pt) 2014-03-20 2017-10-10 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases ?anticorpo da proteína e2 de vírus anti-hepatite c ou fragmento do anticorpo que se liga ao antígeno da mesma, ácido nucleico, e, medicamento?
WO2015187779A1 (en) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
HK1252675A1 (zh) 2015-06-12 2019-05-31 Alector Llc 抗cd33抗体及其使用方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
RU2757314C2 (ru) 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
IL315266A (en) 2016-06-14 2024-10-01 Merck Sharp ַ& Dohme Llc Anti-coagulation factor xi antibodies
WO2018054813A1 (en) 2016-09-20 2018-03-29 Bayer Pharma Aktiengesellschaft Novel antibodies against factor xi and uses thereof

Also Published As

Publication number Publication date
PE20190416A1 (es) 2019-03-19
AR108717A1 (es) 2018-09-19
CN109476758A (zh) 2019-03-15
NZ786442A (en) 2025-06-27
US20200317811A1 (en) 2020-10-08
NI201800134A (es) 2019-03-05
AU2020210233B2 (en) 2024-03-07
IL263272B1 (en) 2025-03-01
JP7277500B2 (ja) 2023-05-19
TN2018000417A1 (en) 2020-06-15
CA3172367A1 (en) 2017-12-21
KR20190018504A (ko) 2019-02-22
IL263272A (en) 2018-12-31
KR102379580B1 (ko) 2022-03-29
AU2017286432B2 (en) 2020-09-24
EP3469002A1 (en) 2019-04-17
GEP20227382B (en) 2022-05-25
JP7022081B2 (ja) 2022-02-17
EA201892716A1 (ru) 2019-05-31
CA3025869C (en) 2025-10-07
JP2021101720A (ja) 2021-07-15
CR20180583A (es) 2019-07-02
KR102218714B1 (ko) 2021-02-24
US11485794B2 (en) 2022-11-01
CL2018003565A1 (es) 2019-03-22
SG11201810763TA (en) 2018-12-28
MY201852A (en) 2024-03-20
BR112018075858A2 (pt) 2019-04-02
PH12018502586A1 (en) 2019-10-07
CN116425879A (zh) 2023-07-14
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
US11512142B2 (en) 2022-11-29
AU2017286432A1 (en) 2018-12-06
US20200255542A1 (en) 2020-08-13
US12275800B2 (en) 2025-04-15
NZ786443A (en) 2025-06-27
NZ786444A (en) 2025-06-27
CO2018013434A2 (es) 2018-12-28
NZ786447A (en) 2025-06-27
NZ748743A (en) 2025-06-27
GEAP202114983A (en) 2021-12-10
MX2023012740A (es) 2024-02-23
IL315266A (en) 2024-10-01
TW201802120A (zh) 2018-01-16
CL2024000367A1 (es) 2024-08-23
KR20210021124A (ko) 2021-02-24
CN109476758B (zh) 2023-05-23
US20200308302A1 (en) 2020-10-01
DOP2018000284A (es) 2019-01-31
MA45234A (fr) 2019-04-17
IL263272B2 (en) 2025-07-01
US11661460B2 (en) 2023-05-30
NZ786448A (en) 2025-06-27
UA129793C2 (uk) 2025-08-06
ECSP18091593A (es) 2019-01-31
MX2018015757A (es) 2019-05-30
US20170355780A1 (en) 2017-12-14
TWI752964B (zh) 2022-01-21
WO2017218371A1 (en) 2017-12-21
US20200270364A1 (en) 2020-08-27
SG10202103120UA (en) 2021-05-28
TWI802193B (zh) 2023-05-11
TW202214702A (zh) 2022-04-16
CA3025869A1 (en) 2017-12-21
AU2020210233A1 (en) 2020-08-20
AU2024201084A1 (en) 2024-03-14
JP2019521978A (ja) 2019-08-08
US11479615B2 (en) 2022-10-25

Similar Documents

Publication Publication Date Title
JOP20180121A1 (ar) أجسام مضادة ضد عامل التخثر xi
MX2021000027A (es) Anticuerpos anti-factor de la coagulacion xi.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
EA201691541A1 (ru) Новые анти-baff антитела
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MX377663B (es) Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
EA201992883A1 (ru) АНТИТЕЛА К TrkB
SG10201806454RA (en) Anti-tenascin c antibodies and uses thereof
MX374286B (es) Compuestos organolepticos novedosos.
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MA39355B2 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201992886A1 (ru) Активируемые антитела против pdl1 и способы их применения
MX374569B (es) Compuestos organolépticos novedosos.
EA201990694A1 (ru) Композиции для лечения деменции